Introduction
Levetiracetam (LEV) has been widely prescribed across Europe as adjunctive treatment of partial-onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures (PGTCS) since its licensing in 2000. The mechanisms of action of LEV appear different from other antiepileptic drugs (AEDs), in that it is thought to act through binding to synaptic vesicle protein 2A thereby interfering with recycling of synaptic vesicles and hence neurotransmitter release. 1 In 2006, licence extension allowed LEV to be used as monotherapy for the treatment of partial-onset seizures. Placebo-controlled studies showed that LEV monotherapy was more effective than placebo against refractory partial-onset seizures in patients who were switched to monotherapy after achieving 50% seizure reduction with adjunctive LEV. 2 Doses of 1000 mg, 2000 mg, and 3000 mg/day were as efficacious as 400 mg, 800 mg, and 1200 mg/day of sustained-release carbamazepine against partial or GTCS in a multicentre, randomized, double-blind head-to-head trial. 3 Although double-blind randomized controlled studies of AEDs are important to establish the efficacy and safety of treatment for regulatory purposes, strict entry and dosing criteria limit the amount of useful data that can be derived to facilitate decision making in routine clinical practice. Pragmatic studies in clinical practice are increasingly recognised to provide data which complement information derived from regulatory trials. 4, 5 The aim of this retrospective audit was to explore outcomes in patients who were prescribed LEV as monotherapy at the Epilepsy Unit at the Western Infirmary, Glasgow, Scotland. , and 8 (3.5%) had unclassified GTCS. LEV was taken as a first AED in 149 (65.4%) who had newly diagnosed epilepsy. The remaining 79 (34.6%) patients already established on AED treatment were switched to LEV because of lack of efficacy (n = 28) or side effects (n = 51) with their previous AED. Overall, the number of seizures prior to starting LEV was 1-30 (median 3); for newly treated patients this was 1-30 (median 3); for switched patients, 1-20 (median 2).
LEV was prescribed initially as 250 mg twice daily for 2 weeks, increasing to 500 mg twice daily for most patients. Some patients who became seizure-free or had very few seizures on 250 mg twice daily elected to remain on this dose. Thereafter, if required, dosing was adjusted as clinically indicated in 500 mg increments. The optimal maintenance dose was identified for each patient according to efficacy and tolerability. As do all patients attending the Epilepsy Unit, patients and/or care givers kept a written record of seizure frequency prior to the addition of and during treatment with LEV. Where possible, patients were reviewed by the same clinician every 6-8 weeks, or sooner if required. Clinical data were recorded in a structured casesheet and entered into a computerised database.
Four primary end-points were established-seizure freedom for at least 1 year on a given dose of LEV, 50% reduction (responder) in seizure frequency over a 12-month period compared with 3-month baseline on the highest tolerated dose of LEV, <50% seizure frequency reduction (marginal effect) over 1 year compared with baseline in patients wishing to continue LEV treatment, or withdrawal of LEV due to lack of efficacy, side effects, or both. The x 2 test was used for comparisons of categoric data. All statistical tests were two-tailed. Calculations were computed using Minitab for Windows (Release 13.32) software.
Results
Of the 228 patients taking LEV monotherapy, 112 (49.1%) remained seizure-free for 1 year (Table 1) . Seizure freedom was achieved in 46.6% (75 of 161) of patients with partial-onset seizures, 54.2% (32 of 59) of patients with idiopathic generalized epilepsies (20 PGTCS, 10 JME, 2 JAE), and 62.5% (5 of 8) of patients with unclassified GTCS. Median duration of treatment was 12 months (range 12-36 months). The median LEV dose in seizurefree patients was 1000 mg/day (range 500-3000 mg/day). Patients were more likely to achieve seizure freedom with LEV as a first monotherapy (81 of 149 [54.4%]), as opposed to switching from another AED (31 of 79 [39.2%]; p = 0.03) (Fig. 1) . In those who switched, seizure freedom was more likely when the switch was made after failing a 1st or 2nd AED (n = 39 of 64 [60.9%]), compared to later in the treatment schedule (n = 2 of 15 [13.3%]; p = 0.029) (Fig. 2) . Seven patients with learning disabilities, all with partial-onset seizures, were started on LEV monotherapy (median dose 1000 mg/day, range 500-2000 mg/ day). Of these, 4 were commenced on the drug as their first treatment, and 3 were switched to LEV. Five became seizure-free, and 2 had a 50% reduction in seizures. PGTCS, primary generalized tonic-clonic seizures; JME, juvenile myoclonic epilepsy; JAE, juvenile absence epilepsy; GTCS, generalized tonic-clonic seizures. At a median dose of 1000 mg/day (range 500-3000 mg/day) LEV was withdrawn in 37 (16.2%) patients (30 [13.1%] side effects, 7 [3.1%] lack of efficacy). Side effects leading to withdrawal are listed in Table 2 . Neuropsychiatric symptoms (7 aggression, 7 mood swings, 2 irritability, 2 depression) led to LEV discontinuation in 18 (7.9%) patients. Other reasons for discontinuation included sedation (n = 5) and lethargy (n = 4). LEV dosing varied widely in all four outcome groups, from seizure freedom on 500 mg daily to withdrawal on 3000 mg daily (Fig. 4) .
Discussion
Of the 228 patients taking LEV monotherapy, 49.1% remained seizure-free for 1 year. This is a little lower than that found in the randomized, controlled study comparing LEV monotherapy with sustained release carbamazepine where 56.6% of patients randomized to receive LEV were seizure-free for 1 year. 3 However, apart from marked differences in methodologies, the randomized trial was performed in patients with newly diagnosed epilepsy only, and this audit studied patients with new-onset and already treated seizures. When analysis was performed on newly diagnosed patients only, the seizure-free percentage rose to 54.4%, which was almost identical to that in the regulatory trial. Not surprisingly, the percentage of patients achieving seizure freedom on switching to LEV from another AED was much lower at 39.2%. 6 Patients with a variety of seizure types and syndromes benefitted from LEV monotherapy. Of the 161 with focal-onset seizures, 46.6% became seizure-free. This is a similar percentage compared with other retrospective analyses. Six (46.2%) of 13 patients with partial-onset seizures who were commenced on LEV had no seizures over a 6-month period. 7 Of 46 adults with partialonset seizures, 17 (36.9%) remained seizure-free at 1 year having switched to, or started LEV monotherapy de novo. 8 LEV monotherapy resulted in 8 of 14 (57.1%) elderly patients with focal-onset seizures gaining complete seizure control over 6 months. 9 A prospective, observational study found that 72% of 25 patients with Alzheimer's disease became seizure-free for at least 1 year with the AED. 10 A prospective, randomized parallel-group casecontrol study of 95 patients with Alzheimer's disease taking LEV (n = 38), phenobarbital (n = 28), or lamotrigine (n = 29) over 13 months found no difference in efficacy between the 3 AEDs (29% LEV, 29% phenobarbital, 24% lamotrigine seizure-free). 11 LEV was associated with fewer adverse events and improved cognitive performance. The median LEV dose in seizure-free patients was 1000 mg/day (range 500-3000 mg/day). LEV dosing varied widely in all four outcome groups. In a responder-selected monotherapy study, seizure-free patients took 3000 mg daily of the AED. 2 When LEV monotherapy was compared with controlled release carbamazepine, seizure freedom was achieved with 1000-3000 mg/day with 86% of responders taking just 1000 mg LEV per day, mirroring the results from this audit. 3 Other monotherapy audits have reported complete seizure control with 1000-2000 mg/day 10 and 2000-5000 mg/day. 7, 8 Patients with <5 seizures prior to the introduction of LEV were more likely to become seizure-free compared to those with 5 seizures. A high number of pre-treatment seizures have been shown previously to be a poor prognostic indicator. [12] [13] [14] Of the 7 patients with learning disabilities started on LEV monotherapy, 5 became seizure-free and 2 had a 50% reduction in seizure activity. There are no published monotherapy data with which to compare these results. In a prospective multicentre openlabel study in 42 patients with epilepsy and learning disabilities, adjunctive LEV reduced median seizure frequency from 4.3 per week to 2.2 per week over 6 months. 15 A Glasgow audit of outcomes with adjunctive LEV in 156 patients with learning disabilities concluded that 40 (26%) became seizure-free for at least 6 months, with 33 (21%) having a 50% reduction in seizure frequency for 6 months, compared with baseline. 16 Of the seizure-free patients, 25 (63%) took 1000 mg or less of the drug. LEV was withdrawn in 15.7% of patients, the majority of whom developed intolerable side effects on a wide range of doses. Aggression and mood swings were the commonest symptoms leading to drug withdrawal. Around 50% of patients who discontinued LEV because of side effects did so due to neuropsychiatric symptoms (aggression, mood swings, irritability, depression). Other side effects comprised sedation, lethargy, nausea, vomiting, ataxia and dizziness. These are in keeping with symptoms reported in the LEV arm of the multicentre randomized trial comparing the monotherapy with sustained-release carbamazepine. 3 
Conclusion
This retrospective audit has shown that treatment with LEV monotherapy resulted in around half of patients remaining seizure-free for at least 1 year on a median dose of 1000 mg/day. The drug was effective across a range of seizure types and syndromes. Seizure freedom was more likely in those who had had <5 pre-treatment seizures, compared to those with 5 seizures, and in those taking the drug as a first monotherapy, as opposed to those switched from another AED. Commonest side effects leading to drug withdrawal included aggression, mood swings, irritability, and depression, which are similar to those reported in patients treated with adjunctive LEV.
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